Hexarelin

What it is

Hexarelin is a synthetic hexapeptide in the growth hormone-releasing peptide (GHRP) family, related to compounds like GHRP-6 but developed as a more potent GH secretagogue. Like the rest of that family, it works by binding the ghrelin receptor rather than mimicking GHRH directly, and it has one of the larger human dose-response datasets among the GHRPs, mostly from studies run in the 1990s.

What the human research found

Imbimbo and colleagues, in a double-blind, placebo-controlled study published in the European Journal of Clinical Pharmacology in 1994, gave twelve healthy adult men single intravenous doses of hexarelin at 0.5, 1 and 2 micrograms per kilogram of body weight.[1] Growth hormone rose in a clearly dose-dependent way, peaking around 30 minutes post-injection and returning to baseline within about four hours. Separate work compared hexarelin directly against GHRH(1-29) in patients with homozygous beta-thalassemia, finding hexarelin produced a larger GH release at an equivalent dose, one of the pieces of evidence behind its reputation as an unusually potent secretagogue in this class.[2]

The catch most listings leave out

Potency is not the whole story with hexarelin, and it's the part of the research that vendor copy for this class of peptide tends to skip. Hexarelin's own literature documents a desensitization effect: repeated dosing blunts the GH response over time more than is typically described for lower-potency GHRPs like GHRP-6 or ipamorelin, which is part of why it fell out of favor relative to those alternatives even within the research-peptide community. Separately from the GH axis, hexarelin has also been studied for direct cardioprotective effects in animal models of cardiac injury, a research thread that runs independently of its GH-secretagogue activity and has not been tested in humans for that purpose.[3]

No vendor is currently listing this

Hexarelin isn't available from any vendor we currently track. It was last seen at $15.20 per mg on Penguin Peptides, 2 July 2026, listed as a 5 mg vial for $76.00. That figure is included here for reference. It's what the compound was actually selling for the last time we confirmed a listing, not a price you can act on today. If a vendor relists it, this page will reflect the live price the next time our data updates.

Related research notes